Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 504

1.

Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics.

Chien RN, Liaw YF.

J Viral Hepat. 2019 Dec 23. doi: 10.1111/jvh.13253. [Epub ahead of print]

PMID:
31868280
2.

Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients.

Liaw YF, Jeng WJ.

Gut. 2019 Nov 29. pii: gutjnl-2019-320341. doi: 10.1136/gutjnl-2019-320341. [Epub ahead of print] No abstract available.

PMID:
31784470
3.

Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.

Liaw YF.

Hepatol Int. 2019 Nov;13(6):665-673. doi: 10.1007/s12072-019-09989-6. Epub 2019 Sep 26. Review.

PMID:
31559604
4.

Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection.

Liaw YF.

Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):631-641. doi: 10.1038/s41575-019-0197-8. Epub 2019 Sep 2. Review.

PMID:
31477873
5.

Taiwan's health-care system and administration are independent of China.

Tsai DH, Lee MH, Chen DS, Liaw YF, Yang PC, Huang YH, Chen CJ.

Lancet. 2019 Oct 26;394(10208):1516. doi: 10.1016/S0140-6736(19)31622-8. Epub 2019 Jul 15. No abstract available.

PMID:
31320198
6.

Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients.

Jeng WJ, Chang ML, Liaw YF.

J Viral Hepat. 2019 Aug;26(8):1019-1026. doi: 10.1111/jvh.13114. Epub 2019 Jun 2.

PMID:
31009126
7.

Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.

Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):538-544. doi: 10.1016/S2468-1253(19)30087-1. Epub 2019 Apr 9.

PMID:
30975477
8.

Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.

Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, Kao JH, Lampertico P, Liaw YF, Motoc A, Papatheodoridis GV, Piratvisuth T, Plesniak R, Wat C.

J Viral Hepat. 2019 Sep;26(9):1040-1049. doi: 10.1111/jvh.13107. Epub 2019 Jul 23.

PMID:
30972912
9.

Taiwan consensus statement on the management of chronic hepatitis B.

Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF.

J Formos Med Assoc. 2019 Jan;118(1 Pt 1):7-38. doi: 10.1016/j.jfma.2018.11.008. Epub 2018 Dec 6.

10.

Gender Impacts on the Disease Severity of Overt Acute Hepatitis A: Different from Overt Acute Hepatitis B.

Chang ML, Liaw YF.

Dig Dis Sci. 2019 Feb;64(2):570-575. doi: 10.1007/s10620-018-5340-9. Epub 2018 Oct 25.

PMID:
30361808
11.

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.

Wei L, Wedemeyer H, Liaw YF, Chan HL, Piratvisuth T, Marcellin P, Jia J, Tan D, Chow WC, Brunetto MR, Diago M, Gurel S, Morozov V, He H, Zhu Y, Wat C, Surujbally B, Thompson AJ.

PLoS One. 2018 Jul 17;13(7):e0199198. doi: 10.1371/journal.pone.0199198. eCollection 2018.

12.

Letter to the Editor: Age at Hepatitis B e Antigen Seroconversion and Other Factors for Outcomes of Chronic Hepatitis B.

Chu CM, Liaw YF.

Hepatology. 2019 Jun;69(6):2711. doi: 10.1002/hep.30179. Epub 2019 May 20. No abstract available.

PMID:
30014494
13.

Immune Responses and Hepatitis B Surface Antigen Loss After Cessation of Direct Antiviral Therapy in Hepatitis B e Antigen-Negative Patients.

Liaw YF.

J Infect Dis. 2018 Oct 20;218(11):1852-1853. doi: 10.1093/infdis/jiy395. No abstract available.

PMID:
29982591
14.

Reply to "letter to the editor"-combination therapy for chronic hepatitis B: The future and beyond.

Hsu CW, Chien RN, Liaw YF.

J Formos Med Assoc. 2018 Aug;117(8):747-748. doi: 10.1016/j.jfma.2018.05.022. Epub 2018 Jun 19. No abstract available.

15.

Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B.

Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, Tsai CC, Ho MC, Lee WC, Yu HC, Shen YY, Eng HL, Wang J, Tseng HH, Jeng YM, Yeh CT, Chen CL, Chen PJ, Liaw YF.

Hepatol Commun. 2018 Apr 18;2(6):747-759. doi: 10.1002/hep4.1182. eCollection 2018 Jun.

16.

HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients.

Liaw YF, Jeng WJ, Chang ML.

Gastroenterology. 2018 Jun;154(8):2280-2281. doi: 10.1053/j.gastro.2018.03.066. Epub 2018 May 7. No abstract available.

PMID:
29746811
17.

Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients.

Chuang WL, Jia J, Chan HLY, Han KH, Tanwandee T, Tan D, Chen X, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Messinger D, Wat C, Bakalos G, Liaw YF.

Aliment Pharmacol Ther. 2018 May;47(9):1306-1316. doi: 10.1111/apt.14595. Epub 2018 Mar 9.

18.

Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.

Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF.

J Formos Med Assoc. 2018 Jul;117(7):588-597. doi: 10.1016/j.jfma.2017.12.007. Epub 2018 Feb 16.

19.

Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients.

Liaw YF.

J Hepatol. 2018 May;68(5):1102-1104. doi: 10.1016/j.jhep.2017.12.031. Epub 2018 Feb 1. No abstract available.

PMID:
29408696
20.

Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.

Jeng WJ, Chen YC, Liaw YF.

J Viral Hepat. 2018 Apr;25(4):421-428. doi: 10.1111/jvh.12833. Epub 2017 Dec 27.

PMID:
29193573
21.

Prognosis of immune-tolerant phase chronic hepatitis B.

Chu CM, Liaw YF.

Gut. 2018 May;67(5):988. doi: 10.1136/gutjnl-2017-315603. Epub 2017 Nov 25. No abstract available.

PMID:
29175863
22.

Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.

Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF.

Hepatology. 2018 Aug;68(2):425-434. doi: 10.1002/hep.29640. Epub 2018 May 6.

PMID:
29108132
23.

Overt acute hepatitis B is more severe in female patients.

Chang ML, Liaw YF.

Hepatology. 2017 Sep;66(3):995-996. doi: 10.1002/hep.29196. Epub 2017 Jul 18. No abstract available.

PMID:
28370200
24.

Serum HBsAg kinetics in clinical prediction.

Jeng WJ, Liaw YF.

J Hepatol. 2017 Jul;67(1):192-193. doi: 10.1016/j.jhep.2017.01.036. Epub 2017 Mar 16. No abstract available.

PMID:
28315712
25.

Immune Tolerance Phase of Chronic Hepatitis B.

Liaw YF, Chu CM.

Gastroenterology. 2017 Apr;152(5):1245-1246. doi: 10.1053/j.gastro.2016.11.057. Epub 2017 Mar 6. No abstract available.

PMID:
28273436
26.

Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients.

Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN, Liaw YF.

Clin Gastroenterol Hepatol. 2016 Dec;14(12):1813-1820.e1. doi: 10.1016/j.cgh.2016.07.002. Epub 2016 Jul 9.

PMID:
27404969
27.

Letter: clinical outcomes of HBsAg loss in chronic HBV infection - author's reply.

Chen YC, Liaw YF.

Aliment Pharmacol Ther. 2016 Sep;44(5):536-7. doi: 10.1111/apt.13723. No abstract available.

28.

Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma.

Chen YC, Liaw YF.

Aliment Pharmacol Ther. 2016 Jul;44(2):210-1. doi: 10.1111/apt.13674. No abstract available.

29.

The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network.

Chang IC, Huang SF, Chen PJ, Chen CL, Chen CL, Wu CC, Tsai CC, Lee PH, Chen MF, Lee CM, Yu HC, Lo GH, Yeh CT, Hong CC, Eng HL, Wang J, Tseng HH, Hsiao CH, Wu HD, Yen TC, Liaw YF.

Medicine (Baltimore). 2016 Apr;95(15):e3284. doi: 10.1097/MD.0000000000003284.

30.

Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection.

Chen YC, Jeng WJ, Chien RN, Chu CM, Liaw YF.

Aliment Pharmacol Ther. 2016 Jun;43(12):1311-8. doi: 10.1111/apt.13630. Epub 2016 Apr 12.

31.

α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare.

Jeng WJ, Chen YC, Chang ML, Liaw YF.

J Antimicrob Chemother. 2016 Jun;71(6):1601-8. doi: 10.1093/jac/dkw019. Epub 2016 Mar 2.

PMID:
26936920
32.

Pulse Blood Pressure Correlates with Late Outcome in Acute Ischemic Stroke without Significant Culprit Artery Stenosis.

Tien YT, Chang MH, Lee YS, Liaw YF, Chen PL.

J Stroke Cerebrovasc Dis. 2016 May;25(5):1229-1234. doi: 10.1016/j.jstrokecerebrovasdis.2016.02.008. Epub 2016 Feb 28.

PMID:
26935120
33.

Letter: lessons from the 'real-world' entecavir therapy in chronic hepatitis B patients.

Chang ML, Liaw YF.

Aliment Pharmacol Ther. 2016 Apr;43(7):846-7. doi: 10.1111/apt.13553. No abstract available.

34.

Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.

Brouwer WP, Chan HL, Brunetto MR, Martinot-Peignoux M, Arends P, Cornberg M, Cherubini B, Thompson AJ, Liaw YF, Marcellin P, Janssen HL, Hansen BE; Good Practice in using HBsAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group).

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1481-1489.e5. doi: 10.1016/j.cgh.2016.01.019. Epub 2016 Feb 10.

PMID:
26872398
35.

Letter: nucleos(t)ide analogues are good, but not sufficient for hepatitis B virus clearance--author's reply.

Liaw YF.

Aliment Pharmacol Ther. 2016 Mar;43(5):655-6. doi: 10.1111/apt.13510. No abstract available.

36.

Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China.

Chen DS, Liaw YF, Chen CJ, Wu JC, Chuang WL, Peng CY, Chien RN.

Hepatology. 2016 Sep;64(3):1008-9. doi: 10.1002/hep.28378. Epub 2016 Feb 19. No abstract available.

PMID:
26661317
37.

Pharmacotherapeutic options for hepatitis B.

Chen YC, Liaw YF.

Expert Opin Pharmacother. 2016;17(3):355-67. doi: 10.1517/14656566.2016.1118056. Epub 2015 Dec 4. Review.

PMID:
26559942
38.

Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis.

Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF.

Aliment Pharmacol Ther. 2015 Nov;42(10):1182-91. doi: 10.1111/apt.13409. Epub 2015 Sep 18.

39.

Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

Chang ML, Liaw YF, Hadziyannis SJ.

Aliment Pharmacol Ther. 2015 Aug;42(3):243-57. doi: 10.1111/apt.13272. Epub 2015 Jun 10. Review.

40.

Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B.

Marcellin P, Martinot-Peignoux M, Asselah T, Batrla R, Messinger D, Rothe V, Lau G, Liaw YF.

Clin Gastroenterol Hepatol. 2015 Aug;13(8):1532-9.e1. doi: 10.1016/j.cgh.2014.12.017. Epub 2014 Dec 24.

PMID:
25542306
41.

Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation.

Chang ML, Jeng WJ, Liaw YF.

Clin Gastroenterol Hepatol. 2015 May;13(5):979-86. doi: 10.1016/j.cgh.2014.10.023. Epub 2014 Oct 28.

PMID:
25445774
42.

Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma.

Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, Wu CF, Lin CL, Liu CJ, Liaw YF, Lin SM, Chen PJ, Lee SD, Yu MW.

PLoS One. 2014 Nov 26;9(11):e95870. doi: 10.1371/journal.pone.0095870. eCollection 2014.

43.

Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B.

Hadziyannis S, Liaw YF.

Gut. 2015 Jun;64(6):1005-6. doi: 10.1136/gutjnl-2014-308677. Epub 2014 Nov 19. No abstract available.

PMID:
25410164
44.

Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management.

Chang ML, Liaw YF.

J Hepatol. 2014 Dec;61(6):1407-17. doi: 10.1016/j.jhep.2014.08.033. Epub 2014 Aug 29. Review.

45.

Telbivudine improves renal function in patients with chronic hepatitis B.

Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A.

Gastroenterology. 2014 Jan;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031. Epub 2013 Sep 22.

PMID:
24067879
46.

Impact of therapy on the long-term outcome of chronic hepatitis B.

Liaw YF.

Clin Liver Dis. 2013 Aug;17(3):413-23. doi: 10.1016/j.cld.2013.05.005. Epub 2013 Jun 21. Review.

PMID:
23905813
47.

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.

Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF.

Hepatology. 2013 Dec;58(6):1888-96. doi: 10.1002/hep.26549. Epub 2013 Oct 17.

PMID:
23744454
48.

Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy.

Liaw YF.

J Hepatol. 2013 Oct;59(4):880-1. doi: 10.1016/j.jhep.2013.05.007. Epub 2013 May 11. No abstract available.

49.

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.

Hepatology. 2013 Sep;58(3):872-80. doi: 10.1002/hep.26436. Epub 2013 Jul 29.

PMID:
23553752
50.

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV.

J Viral Hepat. 2013 Apr;20(4):e37-46. doi: 10.1111/jvh.12025. Epub 2012 Dec 27.

Supplemental Content

Support Center